Form 8-K - Current report:
SEC Accession No. 0001558370-25-002039
Filing Date
2025-03-03
Accepted
2025-03-03 16:10:12
Documents
15
Period of Report
2025-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K enfn-20250303x8k.htm   iXBRL 8-K 40976
2 EX-99.1 enfn-20250303xex99d1.htm EX-99.1 570134
3 GRAPHIC enfn-20250303xex99d1001.jpg GRAPHIC 4366
  Complete submission text file 0001558370-25-002039.txt   772338

Data Files

Seq Description Document Type Size
4 EX-101.SCH enfn-20250303.xsd EX-101.SCH 3253
5 EX-101.LAB enfn-20250303_lab.xml EX-101.LAB 16576
6 EX-101.PRE enfn-20250303_pre.xml EX-101.PRE 10709
17 EXTRACTED XBRL INSTANCE DOCUMENT enfn-20250303x8k_htm.xml XML 5012
Mailing Address 125 SOUTH CLARK STREET, SUITE 750 CHICAGO IL 60603
Business Address 125 SOUTH CLARK STREET, SUITE 750 CHICAGO IL 60603 (312) 253-9800
Enfusion, Inc. (Filer) CIK: 0001868912 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40949 | Film No.: 25697969
SIC: 7372 Services-Prepackaged Software
(CF Office: 06 Technology)